Spero Therapeutics is trading at $1.26 (+7.20%) following a sharp intraday rebound despite a lack of company-specific news or direct corporate events.
- The move appears consistent with volatile small-cap biotech trading and broader risk rotation rather than fundamental news.
- The stock’s strength is idiosyncratic, as the broader biotech sector is currently weaker with the XBI down 2.16%.
- In the absence of earnings, FDA updates, or analyst headlines, the price action is being treated as momentum-driven trading.